Cytomegalo Virus DNA PCR

CMV DNA PCR is a laboratory test that detects and quantifies cytomegalovirus genetic material using polymerase chain reaction. It identifies active infection, measures viral load for diagnosis and monitoring (especially in newborns, immunocompromised, or transplant patients), guides treatment decisions, and assesses response. Samples include blood, plasma, urine, or tissue; results are sensitive and usually available within hours to days.

A CMV PCR positive result means cytomegalovirus DNA was detected by polymerase chain reaction testing, indicating active viral replication or recent infection. Quantitative PCR measures viral load to assess severity and guide treatment. Interpretation depends on context—blood, tissue, newborn, or immunocompromised patient—and may reflect primary infection, reactivation, or congenital infection. Follow-up with your clinician for monitoring and treatment decisions.

A positive CMV DNA test means cytomegalovirus genetic material is detected in blood or tissue, indicating active viral replication. It may reflect a new infection, reactivation, or congenital infection. Viral load helps assess severity and guide treatment—especially important in pregnancy, newborns, or immunocompromised people. Clinical correlation, repeat monitoring, and specialist evaluation determine need for antiviral therapy and further testing.

Cost varies by country, lab and whether testing is public or private. Typical out-of-pocket ranges: India ≈ ₹1,500–6,000; United States ≈ $50–$400 (higher for specialized quantitative assays); United Kingdom: usually free on the NHS, private labs ≈ £40–£200. Insurance coverage, test type and urgent processing can raise costs; confirm with your laboratory or insurer.

Treat CMV PCR positivity by assessing host risk and symptoms. Immunocompetent, asymptomatic patients usually need observation and repeat testing. Symptomatic, immunocompromised, transplant recipients, neonates, or congenital infections require antiviral therapy—typically IV ganciclovir followed by oral valganciclovir (neonates often receive 6 weeks to 6 months). Consult specialists, monitor viral load, CBC and renal function, and test for resistance if response is inadequate.

CMV positive means laboratory tests detect cytomegalovirus—either the virus itself or antibodies. IgM positivity suggests recent or active infection; IgG positivity indicates past infection and likely immunity. CMV negative means no evidence of past or current infection. Primary CMV during pregnancy or in immunocompromised people can be serious, so positive results often prompt further testing and medical follow-up.